MacroGenics, Inc. (FRA:M55)

Germany flag Germany · Delayed Price · Currency is EUR
1.178
-0.017 (-1.42%)
Last updated: Dec 5, 2025, 8:02 AM CET
-66.11%
Market Cap 74.86M
Revenue (ttm) 108.78M
Net Income (ttm) -64.68M
Shares Out n/a
EPS (ttm) -1.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 1.178
Previous Close 1.195
Day's Range 1.178 - 1.178
52-Week Range 0.900 - 3.360
Beta n/a
RSI 41.39
Earnings Date Nov 19, 2025

About MacroGenics

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 341
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol M55
Full Company Profile

Financial Performance

In 2024, MacroGenics's revenue was $149.96 million, an increase of 155.26% compared to the previous year's $58.75 million. Losses were -$66.97 million, 639.3% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.